REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...